| Literature DB >> 25166038 |
Robert Güerri-Fernández1, Judit Villar-García1, Adolfo Díez-Pérez1, Daniel Prieto-Alhambra2.
Abstract
With the advent of high active antiretroviral therapy there was a significant improvement on HIV subjects survival. Thus, bone changes related to HIV became an important aspect of these individuals. HIV affects bone remodeling causing bone fragility. In addition, antiretroviral therapy may also negatively affect bone metabolism. Several studies describe an increased incidence of fractures in these patients when compared with controls without the disease. The European Society of AIDS (EACS), and other societies, have included guidance on management of osteoporosis in HIV-infected patients emphasizing the identification of patients with low bone mass. Supplementation of calcium and vitamin D and the use of alendronate in these individuals should be recommended on a case base.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25166038 DOI: 10.1590/0004-2730000003323
Source DB: PubMed Journal: Arq Bras Endocrinol Metabol ISSN: 0004-2730